HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Durso, R. Articles by Chase, T. N. Search for Related Content PubMed PubMed Citation Articles by Durso, R. Articles by Chase, T. N.

Lysine vasopressin in Alzheimer disease

Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda. MD

The effect of lysine vasopressin on memory and cognitive deficits in Alzheimer disease was investigated. In a double-blind study, seven patients were given 16 units of lysine vasopressin per day for 10 days and were compared with seven different patients receiving placebo. No significant difference in performance between the vasopressin and placebo-treated groups was found in tests designed to evaluate learning, memory, and perception. However, significantly greater improvement in reaction time was seen in the vasopressin-treated group, although this effect was delayed and may have been contributed to by factors other than drug activity.

Address correspondence and reprint requests to Dr. Durso, Boston Veterans Administration Medical Center, Neurology Department. 150 South Huntington Avenue, Boston. MA 0'2130.

Accepted for publication October 16, 1981